One of the few available trials evaluating HIFs in renal replacement therapy patients with COVID-19 is the study by Bao et al.; the administration of roxadustat to patients with COVID-19 receiving peritoneal dialysis improved anemia and was well tolerated, especially among individuals who had difficulty taking EPO [35]. This evidence concerns the gene EPO and COVID-19.